SMALL CAP MOVERS: C4X Discovery cashes in on deal with pharma giant By William Farrington At Proactive Investors For This Is Money Updated: 13:47, 5 January 2024 e-mail View comments It’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall. It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease. Analysts said the payment…
